Machine Learning Engineer, PathAI

PathAI's pioneering spirit is evident through its breakthroughs, exemplified by innovations such as the AIM-HER2 Breast Cancer algorithm. This tool automates HER2 scoring and introduces a novel approach with additive multiple instance learning (aMIL) heatmaps, offering insights into scoring mechanisms. Additionally, PathAI's PathExplore panel of human interpretable features (HIFs) fosters collaborative research, thus enhancing understanding of the tumor microenvironment.

The next chapter for PathAI will unfold under Roche's leadership, following the company's acquisition in early 2026. Building on a partnership that began in 2021, the merger combines PathAI's AI-powered pathology platform, including it AISight software and companion diagnostic capabilities, with Roche's global diagnostic infrastructure. By scaling these technologies worldwide and strengthening capabilities in precision medicines, biomarker discovers, and clinical research, the acquisition is expected to accelerate the adoption of AI-driven pathology and further PathAI's mission of improving patient outcomes through faster, more accurate diagnostics.